Drug metabolism and personalized therapy最新文献

{"title":"Impact of FCGR2A R131H, FCGR3A F158V and FCGR3B NA1/NA2 polymorphisms on response to Fc-containing TNF inhibitors in Tunisian rheumatoid arthritis patients.","authors":"Mahmoud Ines,&nbsp;Moalla Myriam,&nbsp;Ben Tekaya Aicha,&nbsp;Bouden Selma,&nbsp;Rouached Leila,&nbsp;Tekaya Rawdha,&nbsp;Saidane Olfa,&nbsp;Gorji Yousr,&nbsp;Elleuch Mohamed,&nbsp;Laatar Ahmed,&nbsp;Hamdi Wafa,&nbsp;Abdelmoula Leila,&nbsp;Sfar Imen","doi":"10.1515/dmpt-2022-0176","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0176","url":null,"abstract":"<p><strong>Objectives: </strong>Single nucleotid polymorphisms (SNPs) of Fc-gamma receptors (FcgRs), by inducing a variation of their affinity to the Fc-region of immunoglobulins, might influence the efficacy of Fc-containing biologics prescribed in rheumatoid arthritis (RA). Our aim was to investigate associations of <i>FCGR2A</i>, <i>FCGR3A</i> and <i>FCGR3B</i> SNPs with TNF-inhibitors (TNFi)' response in Tunisian RA patients.</p><p><strong>Methods: </strong>A cross-sectional, observational and analytic multicentric cohort study was conducted in a group of 47 Tunisian RA patients treated with (etanercept [ETA], adalimumab [ADL] and infliximab [IFX]). Treatment outcome was evaluated after 6 months. <i>R131H-FCGR2A</i>, <i>F158V-FCGR3A</i> and <i>NA1/NA2-FCGR3B</i> SNPs were genotyped.</p><p><strong>Results: </strong>The analytic study including all types of TNFi showed that <i>FCGR3A-F/F</i> low-affinity receptor was associated with a greater decrease of DAS28, while <i>FCGR3B-NA1/NA1</i> high-affinity receptor was associated with a lower decrease of DAS28 in ADL group. Furthermore, both of high affinity receptors <i>FCGR3B-NA1/NA1</i> and <i>FCGR3A-V/V</i> were more prevalent in non-responders to ADL, according to EULAR criteria.</p><p><strong>Conclusions: </strong>Identifying reliable biomarkers of response to biologics in RA is necessary to improve responsiveness, preserve joints' functions and structure, and reduce treatment's cost. Our study showed that FCGR3A and FCGR3B polymorphisms might have an impact on TNFis' response in RA Tunisian patients since bad response was more frequent in homozygous carriers of high affinity alleles FCGR3A-V and FCGR3B-NA1.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 2","pages":"155-162"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9629860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>CYP2C9</i> gene polymorphisms influence on antihypertensive effectiveness and hypouricemic effect of losartan among patients with arterial hypertension: an observational study.","authors":"Irina I Sinitsina,&nbsp;Alexey V Boyarko,&nbsp;Ilyas I Temirbulatov,&nbsp;Dmitry A Sychev,&nbsp;Kristina A Akmalova,&nbsp;Zhannet A Sozaeva,&nbsp;Elena A Grishina,&nbsp;Karin B Mirzaev,&nbsp;Anastasiia V Asoskova,&nbsp;Vladimir P Fisenko","doi":"10.1515/dmpt-2022-0115","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0115","url":null,"abstract":"<p><strong>Objectives: </strong><i>CYP2C9</i> gene polymorphic variants can decrease the effects of losartan, reducing active metabolite (E-3174) formation. Study aims to determine the influence of <i>*2</i> (+430C>T; rs799853) and *3 (+1075A>C; rs1057910) <i>CYP2C9</i> gene polymorphic variants on the hypotensive and uricosuric effect of losartan on patients with arterial hypertension.</p><p><strong>Methods: </strong>Eighty one patients with stage 1-2 arterial hypertension newly diagnosed with ABMP were enrolled in the study. Physicians started losartan treatment and then we measured urine concentration of E-3174/losartan to estimate CYP2C9 activity. After 3-month losartan treatment we compared effectiveness of the therapy with ABPM and plasma uric acid level between carriers of <i>CYP2C9 *1/*1</i> and <i>CYP2C9</i> gene polymorphic variants (<i>*2</i> and <i>*3</i>).</p><p><strong>Results: </strong>Carriage of <i>CYP2C9*2</i> and <i>CYP2C9*3</i> alleles reduced the hypotensive effect of losartan (p<0.001, OR=8.13 (95% CI, 2.75-23.97)). Analysis of the ABPM data revealed that blood pressure was significantly higher in patients with polymorphic genotypes. There was no significant difference in uric acid level in plasma and losartan and its metabolite concentration in urine between genotypes.</p><p><strong>Conclusions: </strong>Carriage of low function polymorphic variants of the <i>CYP2C9</i> gene (<i>*2</i> and <i>*3</i>) reduced the hypotensive effect of losartan according to ABPM and don't affect uric acid level in plasma and E-3174/losartan in urine.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 2","pages":"163-168"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9631989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacogenetics and ethnicity: \"Dr. José María Cantú\" award announcement.","authors":"Ingrid Fricke-Galindo,&nbsp;Adrián LLerena","doi":"10.1515/dmpt-2023-0037","DOIUrl":"https://doi.org/10.1515/dmpt-2023-0037","url":null,"abstract":"","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 2","pages":"121-122"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9683585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative assessment of antioxidant potential of selected homeopathic preparations in clinical practice.","authors":"Arun Kumar,&nbsp;Suneel Prajapati,&nbsp;Mahima Sharma,&nbsp;Tejveer Singh,&nbsp;Neha Choudhary,&nbsp;Alok C Bharti,&nbsp;Rohit Sharma,&nbsp;Pankaj Gupta","doi":"10.1515/dmpt-2022-0169","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0169","url":null,"abstract":"<p><strong>Objectives: </strong>Antioxidant property like radical scavenging is a primary target to elucidate the efficacy mechanism of a drug against diseases linked to oxidative stress such as cancer, metabolic disorders, rheumatoid arthritis, etc. In alternative therapies, homeopathy is one of the preferred choices by patients and clinicians due to its potential to cure chronic and complex illnesses. However, the efficacy of homeopathic preparations at high diluted potencies attracts rational criticism due to insufficient scientific knowledge supporting the mechanism of action. Therefore, an attempt was made to estimate the total phenolic content (TPC) and radical scavenging activity of clinically prescribed homeopathic drugs.</p><p><strong>Methods: </strong>With gallic acid as a reference control, mother tinctures (MTs) and different potencies of <i>Eucalyptus globulus</i> (EG), <i>Syzygium jambolanum</i> (SJ), <i>Ruta graveolens</i> (RG), and <i>Thuja occidentalis</i> (TO) were used to perform Folin-Ciocalteu test, 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS), and 2,2-diphenyl-1-picrylhydrazyl (DPPH) assays.</p><p><strong>Results: </strong>The results showed TPC of MTs equivalent to µg/mL of gallic acid viz; EG (4,872.5 ± 133.2), SJ (8,840.5 ± 14.8), RG (985.6 ± 39.1), and TO (341.5 ± 19.5) with significant ABTS and DPPH radical scavenging potential. Whereas 30C and 200C potencies of each homeopathic drug showed undetectable phenolic content and insignificant radical scavenging potential compared to vehicle control, i.e., alcohol 90% (2.0 ± 1.5).</p><p><strong>Conclusions: </strong>The reported efficacy of 30C and 200C potencies of homeopathic medicines against oxidative stress-related illnesses might be due to mechanisms other than radical scavenging. Furthermore, the assays studied can be helpful in drug standardization and quality control of MTs that are used as starting material in homeopathic preparations.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 2","pages":"179-190"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9631992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of <i>CYP2D6*4</i>, <i>CYP2D6*10</i> polymorphisms on the safety of treatment with timolol maleate in patients with glaucoma.","authors":"Larisa K Moshetova,&nbsp;Maria M Soshina,&nbsp;Ksenia I Turkina,&nbsp;Elena A Grishina,&nbsp;Zhannet A Sozaeva,&nbsp;Anastasia A Kachanova,&nbsp;Kristina A Akmalova,&nbsp;Dmitriy V Ivashchenko,&nbsp;Mikhail S Zastrozhin,&nbsp;Vladimir P Fisenko,&nbsp;Dmitry A Sychev","doi":"10.1515/dmpt-2022-0117","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0117","url":null,"abstract":"<p><strong>Objectives: </strong>Timolol maleate is used for the treatment of glaucoma and metabolized by cytochrome CYP2D6 in the liver. The aim of this study was the evaluation of the influence of <i>CYP2D6*4</i> and <i>CYP2D6*10</i> gene polymorphisms on the safety of medications containing 0.5% of timolol maleate as glaucoma treatment in patients with primary open-angle glaucoma (POAG).</p><p><strong>Methods: </strong>105 patients with POAG were prescribed glaucoma medications, containing 0.5% timolol maleate. The safety of glaucoma treatment was determined by electrocardiography (ECG) (to assess heart rate (HR) and PQ interval) and blood pressure (BP) measurements. The real-time polymerase chain reaction method was used for the detection of single nucleotide polymorphisms (SNP).</p><p><strong>Results: </strong>The risk of adverse drug reactions was higher in patients with the <i>CYP2D6*4</i> GA genotype compared with GG: mean HR change at 1 month (2.88 ± 4.68 and 6.44 ± 5.57, p<0.001) and 6 months (5.14 ± 8.93 and 7.88 ± 5.65, p<0.001), mean PQ interval change at 1 (0.01 ± 0.031 and 0.02 ± 0.022, p=0.003) and 6 months (0.01 ± 0.032 and 0.02 ± 0.024, p=0.003). The risk of adverse drug reactions was higher in patients with the <i>CYP2D6*10</i> CT genotype compared with CC: mean HR change at 1 month (2.94 ± 4.65 and 6.34 ± 5.66, p<0.001) and 6 months (5.20 ± 8.90 and 7.78 ± 5.75, p<0.001), mean PQ interval change at 1 (0.01 ± 0.032 and 0.02 ± 0.021, p=0.014) and 6 months (0.01 ± 0.033 and 0.02 ± 0.022, p=0.014).</p><p><strong>Conclusions: </strong><i>CYP2D6*4</i> and <i>CYP2D6*10</i> gene polymorphisms may affect a higher risk of timolol-induced bradycardia and increased PQ interval of treatment medications containing 0.5% of timolol maleate in patients with POAG.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 2","pages":"143-148"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9627638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanistic role and potential of Ayurvedic herbs as anti-aging therapies.","authors":"Kirti Raina,&nbsp;Ruchika Kumari,&nbsp;Palak Thakur,&nbsp;Rohit Sharma,&nbsp;Randeep Singh,&nbsp;Abhinay Thakur,&nbsp;Vikas Anand,&nbsp;Rohit Sharma,&nbsp;Ashun Chaudhary","doi":"10.1515/dmdi-2023-0024","DOIUrl":"https://doi.org/10.1515/dmdi-2023-0024","url":null,"abstract":"<p><strong>Introduction: </strong>Medicinal plants and herbs are the most important part of the Ayurveda. The term Rasayana in Charaka Samhita confers long life, youthfulness, strong body, freedom from diseases and the plants mentioned in Rsayana possess antiaging property. Aging is the collective term used for the complex detrimental physiological changes that reduce the functional ability of the cell. Oxidative stress, telomeres shortening, inflammation, and mitochondrial dysfunction are the main factors that regulate the aging process. Chronological aging is an irreversible process but the factors causing biological aging can be controlled. Ayurvedic herbs are better for the management of age-related problems. There are several natural bioactive agents present in plants that can delay the aging process in humans. They trigger actions like enhancing gene longevity and telomerase activity, ROS scavenging furthermore regeneration of tissues.</p><p><strong>Content: </strong>The plants mentioned in the Rasayana of Ayurveda have antiaging potential and can be used to solve modern problems related to aging. Some Ayurvedic plants and their antiaging potential has explained in this review. The main causes of aging, medicinal plants and their use as potential antiaging mediator are covered in this study.</p><p><strong>Summary: </strong>The process of aging is still an enigma. It is a complex, irretrievable, dynamic process that involves a number of factors and is subject to a number of environmental and genetic influences. Rasayana aspect has not been much investigated in clinical trials. Aging is considered to result from free radical damage. According to Charaka, Rasayana drugs open the partially or fully blocked channels. Many Rasayanas show free radical scavenging activity and has the potential to mitigate the effects of aging. It gives an overview of the significance of Ayurvedic medicinal plants as a source of inspiration and the use of these plants as remedies for antiaging.</p><p><strong>Outlook: </strong>This study briefly outlooks the causes of aging and how medicinal plants can be used to reverse the aging process. In this study, we discussed the antiaging potential and mechanistic roles of Ayurvedic herbs. These herbs have the properties to slow down the natural process of aging and can successfully manage common age-related problems.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9918602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of <i>EPHX1</i> c.337 T>C and <i>UGT2B7*2</i> genetic polymorphisms on the requirement of carbamazepine maintenance dose in persons with epilepsy (PWE) of Southern part of India: a cross-sectional genetic association study.","authors":"Shravan Venkatraman,&nbsp;Kesavan Ramasamy,&nbsp;Pradeep P Nair,&nbsp;Priyadharsini Rajendran","doi":"10.1515/dmpt-2022-0157","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0157","url":null,"abstract":"<p><strong>Objectives: </strong>Carbamazepine (CBZ) is a first-line antiseizure drug used for focal onset seizures. It exhibits inter-individual variability in plasma carbamazepine levels and there are both genetic and non-genetic factors having a role in the requirement of CBZ maintenance dose. The aim was to study the influence of <i>EPHX1</i> c.337 T>C and <i>UGT2B7*2</i> genetic polymorphisms on CBZ maintenance dose requirement in persons with epilepsy.</p><p><strong>Methods: </strong>Persons with epilepsy (PWE) of both gender of age 15-65 years on carbamazepine monotherapy who had been taking same maintenance dose for one year were eligible. Five milliliter of venous blood was collected in 10% EDTA under aseptic precautions. After centrifugation, the cellular component was used for DNA extraction and genotyping. For three genotypes of <i>EPHX1</i> c.337 T>C and <i>UGT2B7*2</i>, the differences in mean carbamazepine dose were analyzed using Analysis of Variance (ANOVA). An unpaired t-test was used to draw a comparison between the genotypes and CBZ maintenance dose requirement for dominant and recessive models of <i>EPHX1 c.337 T>C</i> and <i>UGT2B7*2</i>. A value of p<0.05 was considered to be statistically significant.</p><p><strong>Results: </strong>For <i>UGT2B7*2</i> (rs 7439366), CT required a higher dose (CT 626 mg/day and TT 523 mg/day) but not found to be significant (p-value 0.167). PWE carrying CT genotype of <i>EPHX1</i> c.337 T>C had 62 mg higher dose when compared to homozygous mutant CC (590 mg/day for CT and 528 mg/day for CC) but p-value was not found to be significant (p-value 0.835).</p><p><strong>Conclusions: </strong>The results of our study done in 115 PWE showed there was a lack of association between SNPs of <i>EPHX1</i> c.337 T>C, <i>UGT2B7*2</i> and CBZ maintenance dose requirement in Southern part of India and this finding has to be confirmed in a larger sample size.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 2","pages":"191-197"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9985118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the efficacy and safety of Unani pharmacopoeial formulations in dermatophytosis (quba) - a randomized controlled trial.","authors":"Saima Naseem,&nbsp;Mohammad Nawab,&nbsp;Syeda Hajra Fatima,&nbsp;Ahmed Minhajuddin,&nbsp;Asif Ahmad Khan","doi":"10.1515/dmpt-2022-0125","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0125","url":null,"abstract":"<p><strong>Objectives: </strong>The recent trends of rising unresponsive cases of dermatophytosis to conventional therapies pose a challenge in clinical practice. Unani medicine offers effective treatment for dermatophytosis. This study aimed to evaluate the efficacy and safety of the Unani herbo-mineral preparations Qurs-e-Asfar (QA) and Rogan-e-Narjeel (RN) in dermatophytosis.</p><p><strong>Methods: </strong>This was a randomized, active-controlled and open-label clinical study. The participants diagnosed with dermatophytosis (n=78) randomized into treatment group (n=40) receiving oral QA (778 mg twice a day) and topical RN and control group (n=38) receiving oral Itraconazole (100 mg/day) and topical Terbinafine hydrochloride (1%) for 6 weeks.</p><p><strong>Results: </strong>We found post-treatment improvement in itching by 86.3% vs. 78% (treatment vs. control group), erythema by 96.4% vs. 94.3%, scaling by 93% vs. 92.2% and peripheral raised margins by 82.3% vs. 81%. Furthermore, this study showed that the differences in the mean Total Signs and Symptoms Score (TSSS) and positive KOH mount were clinically and statistically significant (p<0.05) in both the groups. On comparing inter group, the differences in mean TSSS (p=0.07) and positive KOH mount (p=0.717) were found statistically insignificant.</p><p><strong>Conclusions: </strong>This study concludes that the formulations QA and RN were effective and safe in the treatment of dermatophytosis.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 2","pages":"169-177"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10000785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Actionable mutations in non-small cell lung cancer in patients at hospital de Especialidades Eugenio Espejo, Ecuador 2017-2020.","authors":"Miguel Ángel Fernández Freire,&nbsp;Gabriela Isabel Gálvez Salazar,&nbsp;Mariana Meira Scudeler,&nbsp;Fernanda Rodrigues-Soares,&nbsp;Gabriela Fernanda Jaramillo Koupermann,&nbsp;Andrea Paola Moreno Ocampo","doi":"10.1515/dmpt-2022-0112","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0112","url":null,"abstract":"<p><strong>Objectives: </strong>Determine the frequency of actionable mutations in non-small cell lung cancer (NSCLC) and their correlation with overall survival (OS) and the site of metastases.</p><p><strong>Methods: </strong>We performed a descriptive cross-sectional study at the Hospital de Especialidades Eugenio Espejo, Ecuador, between 2017 and 2020. Demographic, pathological, and molecular alterations in epidermal growth factor (EGFR), Anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), Programmed death-ligand 1 (PD-L1) expression, and clinical data detailed in patients' medical records with metastatic NSCLC were collected and analyzed. Seventy-nine stage IV patients had NSCLC; adenocarcinoma histology represents 56 (70.9%). The predominant mutation was in EGFR (22.8%); the most common variant was the deletion of exon 19 (72.2%). The most common metastatic site was in the contralateral lung (22.3%); however, this variable showed no significant correlation to the molecular markers (p=0.057). The overall survival (OS) and the status of molecular markers are not statistically significant (p=0.27). OS was better for non-mutated EGFR than for mutated EGFR (p=0.012). However, the frequency values are unrelated to contralateral lung metastasis or survival.</p><p><strong>Conclusions: </strong>Our frequency mutations are concordant with those found in other studies in Latin America. EGFR was the most common biomarker mutation, and there was a better OS in EGFR non-mutated patient.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 2","pages":"149-153"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9682544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of pharmacogenetic studies in the Bangladeshi population.","authors":"Md Shaki Mostaid,&nbsp;Md Abdul Aziz,&nbsp;Jeba Atkia Maisha,&nbsp;Mohammad Safiqul Islam,&nbsp;Abdullah Al Maruf","doi":"10.1515/dmpt-2022-0194","DOIUrl":"https://doi.org/10.1515/dmpt-2022-0194","url":null,"abstract":"<p><p>Pharmacogenetics (PGx)-guided prescribing is an evidence-based precision medicine strategy. Although the past two decades have reported significant advancements in both the quality and quantity of PGx research studies, they are seldom done in developing countries like Bangladesh. This review identified and summarized PGx studies conducted in the Bangladeshi population by searching PubMed and Google Scholar. Additionally, a quality evaluation of the identified studies was also carried out. Eleven PGx studies were identified that looked at the effects of genetic variants on blood thinners (<i>CYP2C9</i>, <i>VKORC1</i>, and <i>ITGB3</i>), cancer drugs (<i>TPMT</i>, <i>MTHFR</i>, <i>DPYD</i>, <i>ERCC1</i>, <i>GSTP1</i>, <i>XPC</i>, <i>XRCC1</i>, <i>TP53</i>, <i>XPD</i>, and <i>ABCC4</i>), statins (<i>COQ2</i>, <i>CYP2D6</i>, and <i>CYP3A5</i>), and prednisolone (<i>ABCB1</i>, <i>CYP3A5</i>, and <i>NR3C1</i>) in the Bangladeshi population. Most studies were of low to moderate quality. Although the identified studies demonstrated the potential for PGx testing, the limited PGx literature in the Bangladeshi population poses a significant challenge in the widespread implementation of PGx testing in Bangladesh.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"38 2","pages":"123-131"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10001778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}